Integra LifeSciences missed Q1 expectations, hurting stock despite Q4 beat and improved operations.

Integra LifeSciences reported Q4 2025 revenue of $435 million, a 1.7% decline year-over-year, with earnings per share of $0.83, beating estimates. The company revised its 2026 outlook, projecting revenue of $1.66–1.7 billion and adjusted EPS of $2.30–2.40, slightly below consensus. Despite positive product relaunches and supply chain improvements, the stock fell due to weak Q1 guidance, negative free cash flow, and ongoing tariff impacts.